Mesa Laboratories, Inc. Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes, Including Full Ex...
August 12 2019 - 4:05PM
Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa”) today announced the
closing of its previously announced concurrent underwritten public
offerings of an aggregate of 431,250 shares of its common stock
(the “Shares”) at a public offering price of $210.00 per share for
gross proceeds, before deducting underwriting discounts and
commissions and estimated offering expenses, of approximately $90.6
million, and $172.5 million aggregate principal amount of 1.375%
convertible senior notes due 2025 (the “Notes”), which includes the
exercise in full of the underwriters’ options to purchase 56,250
additional Shares and $22.5 million additional aggregate principal
amount of Notes. The offering of the Shares is expected to result
in approximately $85.0 million in net proceeds to Mesa after
deducting underwriting discounts and commissions and other
estimated offering expenses payable by Mesa. The offering of the
Notes is expected to result in approximately $167.2 million in net
proceeds to Mesa after deducting underwriting discounts and
commissions and other estimated offering expenses payable by Mesa.
Mesa intends to use the net proceeds from the offerings to
continue its acquisition strategy and for general corporate
purposes. Mesa has not entered into any agreements with respect to
any acquisitions at this time.
Jefferies LLC and J.P. Morgan Securities LLC acted as the
representatives of the underwriters for the offerings. Evercore
Group L.L.C. and Wells Fargo Securities, LLC also acted as book
runners on the common stock offering and the notes offering,
respectively, and Janney Montgomery Scott LLC acted as a lead
manager on the common stock offering.
The common stock offering and the notes offering were effected
pursuant to Mesa’s shelf registration statement (including a base
prospectus), which Mesa filed with the Securities and Exchange
Commission (“SEC”). Final prospectus supplements related to the
offerings were filed with the SEC. Copies of the final
prospectuses, including the base prospectus, may be freely obtained
by visiting EDGAR on the SEC website at www.sec.gov. Alternatively,
copies may be obtained from Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at 877-821-7388, or by email at
Prospectus_Department@Jefferies.com, and from J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)
803-9204, or by email at prospectus-eq_fi@jpmchase.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any offer or
sale of, the Shares or the Notes in any state or jurisdiction in
which the offer, solicitation, or sale of the Shares or the Notes
would be unlawful prior to the registration or qualification
thereof under the securities laws of any such state or
jurisdiction.
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. designs, manufactures and markets
quality control products and services. Mesa is headquartered in
Lakewood, Colorado, and operates out of ten physical locations
globally.
Cautionary Language Concerning Forward-Looking
Statements
This press release contains forward-looking statements regarding
our future business expectations, which are subject to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Investors are cautioned that statements in this press
release which are not strictly historical statements, including,
without limitation, statements regarding the anticipated use of
proceeds of the offerings, constitute forward-looking statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” “anticipate,” or “could” and similar expressions.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation,
uncertainties related to market conditions. These and other risks
and uncertainties are described in greater detail in the section
entitled “Risk Factors” in Mesa’s most recent Annual Report on
Form 10-K and Quarterly Report on Form 10-Q on file with the
Securities and Exchange Commission and the other reports that Mesa
periodically files with the Securities and Exchange Commission.
Actual results may differ materially from those Mesa contemplated
by these forward-looking statements. These forward-looking
statements reflect management’s current views and Mesa does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date hereof except as required by law.
Contact:
Gary Owens, President and CEO
John Sakys, CFO
both of Mesa Laboratories, Inc.
303-987-8000
Mesa Laboratories (NASDAQ:MLAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesa Laboratories (NASDAQ:MLAB)
Historical Stock Chart
From Apr 2023 to Apr 2024